Havell E A, Moldawer L L, Helfgott D, Kilian P L, Sehgal P B
Trudeau Institute, Inc., Saranac Lake, NY 12983.
J Immunol. 1992 Mar 1;148(5):1486-92.
It was found that IL-1 is produced in livers and spleens of mice shortly after the i.v. injection of a sublethal or lethal Listeria monocytogenes inoculum. In sublethally infected mice, IL-1 was present in infected livers and spleens by the end of the first day of infection. Thereafter, the amounts of IL-1 in these organs increased and decreased in concordance with bacterial numbers. IL-1 was not present in the peripheral circulation of mice during sublethal listeriosis, but was present in the blood late in lethal infection. Evidence showing that IL-1 plays a role in antibacterial resistance early in listeriosis was obtained through the use of 35F5 mAb that binds to the murine type I IL-1R and functions to block IL-1 alpha and IL-1 beta actions. Blockade of the type I IL-1R by the 35F5 mAb results in greatly enhanced bacterial growth in the livers and spleens of mice that had received a sublethal Listeria inoculum. Consistent with the exacerbation of listeriosis caused by 35F5 mAb, but in contrast to the effect of 35F5 mAb in other murine models, 35F5 mAb-treated mice exhibit markedly elevated levels of IL-6 in their circulation and infected organs.
研究发现,静脉注射亚致死剂量或致死剂量的单核细胞增生李斯特菌接种物后不久,小鼠的肝脏和脾脏中会产生白细胞介素-1(IL-1)。在亚致死感染的小鼠中,感染第一天结束时,感染的肝脏和脾脏中就存在IL-1。此后,这些器官中IL-1的量随着细菌数量的变化而增加和减少。在亚致死性李斯特菌病期间,小鼠的外周循环中不存在IL-1,但在致死性感染后期,血液中会出现IL-1。通过使用与小鼠I型IL-1受体结合并能阻断IL-1α和IL-1β作用的35F5单克隆抗体(mAb),获得了IL-1在李斯特菌病早期发挥抗菌抗性作用的证据。35F5 mAb对I型IL-1受体的阻断导致接受亚致死剂量李斯特菌接种的小鼠肝脏和脾脏中的细菌生长大大增强。与35F5 mAb导致的李斯特菌病恶化一致,但与35F5 mAb在其他小鼠模型中的作用相反,经35F5 mAb处理的小鼠循环系统和感染器官中的IL-6水平显著升高。